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Abstract
The targeting of parasite cysteine proteases with small molecules is emerging as a possible approach to treat tropical
parasitic diseases such as sleeping sickness, Chagas’ disease, and malaria. The homology of parasite cysteine proteases to
the human cathepsins suggests that inhibitors originally developed for the latter may be a source of promising lead
compounds for the former. We describe here the screening of a unique ,2,100-member cathepsin inhibitor library against
five parasite cysteine proteases thought to be relevant in tropical parasitic diseases. Compounds active against parasite
enzymes were subsequently screened against cultured Plasmodium falciparum, Trypanosoma brucei brucei and/or
Trypanosoma cruzi parasites and evaluated for cytotoxicity to mammalian cells. The end products of this effort include the
identification of sub-micromolar cell-active leads as well as the elucidation of structure-activity trends that can guide further
optimization efforts.
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Introduction
There is a critical need for new drugs to treat neglected tropical
diseases [1,2,3,4]. Current therapies are limited by inadequate
efficacy, drug resistance, or toxicity. Chagas’ disease, for example,
remains the leading cause of heart disease in Latin America, with
between 8 and 12 million people currently infected, and over 90
million at risk (as reported in WHO fact sheet No. 340, June
2010). Current therapy for Chagas’ disease consists of the nitro
heterocycles nifurtimox and benznidazole. Both drugs have
frequent and serious side effects [5] limiting their efficacy, and
each requires an extended (60–120 days) course of therapy.
Furthermore, resistance to nifurtimox is emerging. Drug choices
for those suffering from human African trypanosomiasis (HAT,
sleeping sickness) are similarly poor, with organoarsenic deriva-
tives (e.g. melarsoprol) still employed in the treatment of CNS
disease despite a ,5% rate of drug-associated mortality [6]. In the
treatment of malaria, the artemisinin-based combination therapies
(ACT) [7] are currently effective and well tolerated, but resistance
to the partner drugs [8] and possibly to artemisinins as well [9] is
emerging.
One pragmatic strategy to develop new antiparasitic drug leads
is to focus on targets that are shared by multiple pathogens.
Cysteine proteases play essential roles in numerous protozoan and
helminth parasites, and are therefore appropriate targets for
antiparasitic chemotherapy [10]. The Clan CA [11] cysteine
protease cruzain (cruzipain) has been advanced as a potential drug
target in Trypanosoma cruzi, the parasite responsible for Chagas’
disease [12]. Cruzain is highly expressed in the intracellular
amastigote stage of the parasite that is responsible for human
disease. Cruzain deficient strains of the parasite fail to establish
infection in immune-competent experimental hosts [13]. Because
genetic deletion of the cruzain gene is not feasible, the target has
instead been validated with small molecules. Hence, irreversible
inhibitors of cruzain produce a characteristic swelling of the
parasite Golgi compartment in T. cruzi parasites, leading to
subsequent dysmorphic changes in both Golgi and endoplasmic
reticulum, and ultimately rupture of parasite cells [14]. A number
of cysteine protease inhibitors have been shown to arrest T. cruzi
development within mammalian cells in vitro, and some have been
shown to arrest or cure infection in mouse models of disease [15].
In Trypanosoma brucei parasites, the cysteine proteases rhodesain
(brucipain) and a cathepsin-B like protease (TbCatB) have been
advanced as potential drug targets [16,17].
The erythrocytic malaria parasite produces a variety of
proteases that perform the essential function of hemoglobin
hydrolysis, whereby the parasite acquires its principal source of
amino acids [18,19]. We and others have shown that cysteine
protease inhibitors block the hydrolysis of hemoglobin by
erythrocytic parasites, causing the food vacuole to fill with
undegraded hemoglobin, preventing parasite development, and
indicating that cysteine proteases play an essential role in
www.plosntds.org 1 May 2011 | Volume 5 | Issue 5 | e1023
hemoglobin hydrolysis [20]. Among the various proteases that
mediate hemoglobin hydrolysis are the cysteine proteases
falcipain-2 and falcipain-3. Disruption of the falcipain-2 gene
leads to a block in trophozoite hemoglobin hydrolysis [21]; the
falcipain-3 gene could not be disrupted, strongly suggesting that
this protease is essential for erythrocytic parasites [22]. The
inhibition of cysteine protease mediated hydrolysis of hemoglobin
is therefore a promising and active area of drug discovery research
[23,24,25].
A concern in targeting parasite cysteine proteases with
chemotherapeutic agents is the potential for toxicity due to the
existence of homologues such as cathepsin B, K, S, and L in the
mammalian host. This fear has to some extent been alleviated by
pre-clinical experience with cysteine protease inhibitors targeting
plasmodium and trypanosome parasites. Even compounds that are
not significantly selective at the biochemical level have proven to
be well tolerated in animals. Why might this be so? One possibility
is that whereas mammalian cysteine proteases are a redundant
gene family in which many discreet catalytic types occur in the
same lysosome or vacuolar compartment, parasite enzymes –
although sometimes part of a small gene family – tend to be less
redundant [26]. A second factor is that the host-origin lysosomal
cysteine proteases are present in mammalian organelles at
millimolar concentrations, much higher than is thought to be
the case for the parasite proteases [27,28]. As such, it would be
difficult to completely eliminate host cathepsin activity in the
context of a short course of therapy targeting an acute infection.
Nevertheless, a team of academic and industry researchers
recently reported a series of nitrile-based cruzain inhibitors that
display excellent in vitro selectivity for the parasite protease over
mammalian cathepsins [29].
The cysteine protease inhibitor library screened in this study is
unique and not commercially available. It is composed entirely of
compounds synthesized by medicinal chemists at Celera Geno-
mics in the course of various discovery campaigns targeting
human cathepsins, primarily cathepsins K, S, and B
[30,31,32,33]. The library members are generally peptidic in
nature and nearly all possess an electrophilic ‘‘warhead’’ that
engages the active-site cysteine thiol reversibly or irreversibly
through the formation of a C-S bond. The topic of irreversible
enzyme inhibition continues to generate healthy debate, with
reversible (even if covalent-reversible) modes of inhibition
generally viewed as being preferable [34]. This position seems
prudent in the case of chronic conditions where long-term safety
in very large patient populations is of paramount importance
(e.g., in osteoporosis). In the case of an acute infection however,
irreversible inhibition is arguably advantageous, a view that has
been advanced in recent review articles [35,36]. In any event, the
focus of the Celera group on chronic disorders like osteoporosis is
reflected in the constitution of the inhibitor library, which is
heavily biased towards reversible-covalent type inhibitors, most
notably aminoacetonitriles and heterocyclic ketones. The library
contains a much smaller number of irreversible inhibitors, such as
fluoromethylketones [37] and vinylsulfones [30]. The objective of
the study described herein was to mine this library of ,2100
unique cathepsin inhibitors to identify target- and parasite-active
lead compounds. This discovery paradigm seeks to leverage
chemical entities already in existence for a new purpose, much
akin to the re-purposing of approved drugs. An important
advantage of re-purposing at the lead stage, however, is that it
allows for subsequent optimization of drug properties specific to
the antiparasitic indication.
Methods
Cysteine protease assays
Recombinant cruzain, rhodesain, TbCatB, falcipain-2 and
falcipain-3 were expressed as described previously [38,39,
40,41,42]. Inhibitor stock solutions were prepared in DMSO
and screened at 0.1 mM for cruzain and rhodesain, 1 mM for
TbCatB and 50 nM for falcipain-3 (0.5% DMSO in assay). For
IC50 determinations, compounds were serially diluted in DMSO
in the range of 25 mM – 0.001 mM for cruzain, rhodesain and
TbCatB; and 5 mM – 0.06 nM for falcipain-2 and falcipain-3.
Protease inhibition assays for cruzain and rhodesain were carried
out in 96 well plate format as described previously [43]. Cruzain
(4 nM), rhodesain (4 nM) or TbCatB (258 nM) was incubated
with test compound in 100 mM sodium acetate, pH 5.5,
containing 5 mM DTT and 0.01% Triton X-100 (buffer A), for
5 min at room temperature (the higher concentration of TbCatB
was required due to its lower intrinsic activity against the
fluorogenic substrate). Then buffer A containing Z-Phe-Arg-
AMC (Bachem) was added to enzyme-compound mixture to give
10 mM substrate in a final assay volume of 200 mL. The rate of
free AMC release was measured at excitation and emission
wavelengths of 355 and 460 nm, respectively, with a microtiter
plate spectrofluorimeter (SpectraMax M5, Molecular Devices) for
3 min. Percentage inhibition of test compound was calculated
relative to the DMSO control (0% inhibition control). IC50 values
were determined with Prism 4 software (GraphPad, San Diego,
CA) using sigmoidal dose-response variable slope model.
Protease inhibition assays for falcipain-2 and falcipain-3 were
carried out in 96 well plate format as described previously [42,43]
with modification for end-point readout. Falcipain-2 (21 nM) or
falcipain-3 (78 nM) was incubated with test compound for
10 min at room temperature in 200 mM sodium acetate, pH 6,
10 mM DTT and 3.6% glycerol and 0.01% Triton X-100 (buffer
B). Then buffer B containing Z-Leu-Arg-AMC (Bachem) was
added to the enzyme-compound mixture to give 25 mM substrate
in a final assay volume of 200 mL. After 15 min, 50 mL of 5 M
acetic acid was added to each well to stop the reaction. End-point
fluorescence was read in a spectrofluorimeter as above. The 0%
inhibition control wells contained DMSO while 100% inhibition
control wells contained 50 mM E-64 (Sigma). Percentage
inhibition of test compound was calculated relative to the
controls and IC50 curve fitting was performed with Prism 4
software as above.
Author Summary
Diseases like malaria and sleeping sickness are caused by
tropical parasites and represent a major cause of mortality
and morbidity in the developing world. A pragmatic
approach to discover new drugs for these diseases is to
search for drug leads among existing small molecule
collections generated in the for-profit pharmaceutical
industry. In this study, we searched for new drug leads
among a collection of small molecules donated by Celera
Genomics. This collection of molecules was originally
developed to inhibit a class of human enzymes (cathep-
sins) implicated in diseases like osteoporosis and psoriasis.
Similar enzymes are also present in most tropical parasites,
making this collection a logical place to search for new
drug leads. The end result of this effort saw the
identification of compounds that inhibit the growth of
one or more tropical parasites and that will serve as good
starting points for the development of new drugs for
tropical parasitic diseases.
New Antiparasitic Drug Leads
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Trypanothione reductase assay
The enzyme inhibition assay was carried out in 96 well plate
format as described previously [44] with modification in the
sequence of substrate addition. Trypanothione reductase (3 mU/
mL) was incubated with 10 mM test compound (1% DMSO in
assay) for 30 min at room temperature in the presence of 50 mM
DTNB (5,59-Dithiobis(2-nitrobenzoic acid), 6 mM trypanothione,
40 mM Hepes pH 7.4 and 1 mM EDTA. Then 150 mM NADPH
was added to give a final assay volume of 100 mL. The rate of
TNB (2-nitro-5-mercaptobenzoic acid; yellow color) formation
was measured in absorbance at 412 nm with a microtiter plate
spectrofluorimeter (Flexstation, Molecular Devices). Percentage
inhibition was determined with respect to the 0% inhibition
control (1% DMSO).
T. brucei brucei assay
The growth inhibition assay for T. brucei brucei was conducted as
described previously [45]. Bloodstream forms of the monomorphic
T. brucei brucei clone 427-221a were grown in complete HMI-9
medium containing 10% FBS, 10% Serum Plus medium (Sigma
Inc. St. Louis Mo. USA), 50 U/mL penicillin and 50 mg/mL
streptomycin (Invitrogen) at 37uC under a humidified atmosphere
and 5% CO2. Inhibitor stocks were prepared in 100% DMSO and
screened at 5 mM for percent inhibition values or serially diluted
from 25 mM to 0.04 mM in 10% DMSO for IC50 determinations.
5 mL of each dilution was added to 95 mL of diluted parasites
(16104 cells per well) in sterile Greiner 96-well flat white opaque
culture plates such that the final DMSO concentration was 0.5%.
The 0% inhibition control wells contained 0.5% DMSO while
100% inhibition control wells contained 50 mM thimerosal
(Sigma). After compound addition, plates were incubated for
40 hours at 37uC. At the end of the incubation period, 50 mL of
CellTiter-GloTM reagent (Promega Inc., Madison, WI, USA) was
added to each well and plates were placed on an orbital shaker at
room temperature for 2 min to induce lysis. After an additional
10 min incubation without shaking to stabilize the signal, the
ATP-bioluminescence of each well was determined using an
Analyst HT plate reader (Molecular Devices, Sunnyvale, CA,
USA). Raw values were converted to log10 and percentage
inhibition calculated relative to the controls. IC50 curve fittings
were performed with Prism 4 software as above.
Jurkat cell cytotoxicity assay
Jurkat cells (clone E6-1) were grown in complete RPMI-1640
medium containing 10% FBS, 50 U/mL penicillin and 50 mg/mL
streptomycin (Invitrogen) at 37uC under a humidified atmosphere
Figure 1. Structural composition of the cathepsin inhibitor library. Illustrated are significantly represented chemotypes at three positions:
warhead/P1, P2, and P3. Indicated in parentheses are the approximate number of library members possessing each substructural chemotype.
doi:10.1371/journal.pntd.0001023.g001
New Antiparasitic Drug Leads
www.plosntds.org 3 May 2011 | Volume 5 | Issue 5 | e1023
and 5% CO2. For cytotoxicity testing, cells were diluted to 1610
5
per ml in complete RPMI-1640 medium. Test compound stocks
were prepared in 100% DMSO and screened at 10 mM against
cells (16104 cells per well) in sterile Greiner 96-well flat white
opaque culture plates (0.5% final DMSO concentration). The 0%
inhibition control wells contained 0.5% DMSO while 100%
inhibition control wells contained 40 mM staurosporine. After
compound addition, plates were incubated for 40 hr at 37uC. At
the end of the incubation period, 50 mL of CellTiter-GloTM
reagent (Promega Inc., Madison, WI, USA) was added to each
well and plates were placed on an orbital shaker at room
temperature for 2 min to induce lysis. After a further 10 min
incubation without shaking to stabilize the signal, the ATP-
bioluminescence of each well was determined using an Analyst HT
plate reader (Molecular Devices, Sunnyvale, CA, USA). Calcula-
tions of percentage inhibition and IC50 were performed similar to
those in the T. brucei brucei assay.
P. falciparum assay
The growth inhibition assay for P. falciparum was conducted as
described previously [43]. W2-strain P. falciparum parasites (1%
parasitemia, 2% hematocrit) were cultured at 37uC in human red
blood cells under the atmosphere of 3% O2, 5% CO2 balance N2
in 0.2 mL of per well in medium RPMI-1640 supplemented with
10% human serum in duplicate 96-well flat bottom culture plates
in the presence of inhibitors. Tested compounds were serially
diluted 1:3 in the range 10,000 – 4.6 nM, with maximum DMSO
concentration of 0.1%. Following 48 hours of incubation, the
medium was removed and the cells were fixed in 2% formalde-
hyde in PBS. Parasite growth was evaluated by flow cytometry on
a FACsort (Becton Dickinson) equipped with AMS-1 loader (Cytek
Development) after staining with 1 nM DNA dye YOYO-
1(Molecular Probes) in 100 mM NH4Cl, 0.8% NaCl. Parasitemias
were determined from dot plots (forward scatter vs. fluorescence)
using CELLQUEST software (Becton Dickinson). IC50 values for
growth inhibition were determined from plots of percentage
control parasitemia over inhibitor concentration using GraphPad
Prism software.
T. cruzi amastigote assay
The growth inhibition assay for the intracellular T. cruzi was
conducted in 96-well plate format as described previously [28].
Briefly, bovine embryo skeletal muscle (BESM) cells (26103/well),
seeded overnight, were infected with CA-I/72 T. cruzi trypomas-
tigotes (26103/well). Sixteen hours post-infection, test compounds
(serial dilution concentrations starting from 20 mM) were added
and assay plates were incubated for an additional 72 hours at
37uC with 5% CO2. Cells were then washed once in PBS, fixed
with 4% paraformaldehyde and stained with DNA fluorescent dye
DAPI (49 6-diamidino-2-phenylindole). The assay plates were then
imaged in the IN Cell Analyzer 2000 (GE Healthcare) with the
excitation and emission filters set of 350 nm and 460 nm,
respectively, to detect DAPI signals. The feature extraction
module in IN Cell Developer Toolbox 1.7 software was used to
count host nuclei and parasite kinetoplasts by size difference.
Cathepsin inhibitor library
The library was donated by Celera Genomics to the Sandler
Center for Basic Research in Parasitic Disease at UCSF. The
structural constitution of the library is summarized below
(Figure 1). The vast majority of the compounds contain a biaryl
or biheteroaryl ring system at the P3 position, a natural or
unnatural amino acid at P2, and a thiol-reactive warhead function
with or without a P1 substituent. Nearly three quarters of the
library members are of the aminoacetonitrile warhead type and
lack any P1 side chain; around 100 nitrile analogs possess a
geminal (cyclic) substituent at P1. Other abundant inhibitor
chemotypes include ,170 ketobenzoxazoles, ,50 ketooxadia-
zoles, and ,80 a-hydroxy/alkoxy ketones. Around 50 irreversible
inhibitors of the vinylsulfone type are present, as are a smaller
number of other warheads. The majority of ketone and
vinylsulfone warheads also contain a P1 side chain, and the
majority of these are unbranched aliphatics of between two and
four carbons, or are phenethyl.
The varieties of P2 side chains present in the library reflect the
substrate specificity of the proteases being targeted and are heavily
biased towards leucine and phenylalanine type side chains. A large
number of analogs contain more extended P2 side chains (e.g.,
homo-phenylalanine or benzyl-cysteine), branching substituents
and/or halogenations on the aromatic ring. About 60 analogs
contain a geminal disubstituted (cyclic) moiety at P2. The majority
of inhibitors are capped on their N-termini with benzoyl, acyl,
carbamoyl (e.g., Cbz), or urea functions. Both aryl and heteroaryl
P3 groups are represented, and many are highly substituted or
bear an additional pendant aryl or heteroaryl ring substituent.
Around 500 analogs contain such a biaryl or heterobiaryl P3
moiety and para-substituted biaryls are greater in number than
meta- or ortho-substituted biaryls.
Results
Evaluation of the cathepsin inhibitor library was envisioned to
begin with a single-concentration screen which would be followed
by analysis of actives in full dose-response and against cultured
parasites. The determination of inhibition kinetics was deemed
impractical given the size of the library. Still, we recognized the
perils of comparing IC50 values between reversible and
irreversible inhibitors, since inhibition by the latter is expected
to be time dependent. We therefore first evaluated time-
dependence of inhibition for a small but representative subset
of the library (Table 1). Test compounds were pre-incubated with
falcipain-3 for 0, 10, or 60 minutes prior to addition of a
fluorogenic protease substrate. As expected, inhibitor types
Table 1. Effects of pre-incubation time on falcipain-3 IC50
values for inhibitors of different chemotype.
Falcipain-3 IC50 (nM) pre-incubation time
Compound Chemotype 0 minute 10 minute 60 minute
1 Acyloxyketone 19 8 2
2 Aldehyde 5 4 4
3 Fluoromethylketone 97 30 8
4 Hydroxyketone 9 11 14
5 Ketoamide 20 19 22
6 Ketoheterocycle 8 7 6
7 Ketoheterocycle 8 9 10
8 Ketoheterocycle 10 8 7
9 Ketoheterocycle 3 3 3
10 Nitrile 41 44 50
11 Nitrile 5 3 3
12 Nitrile 15 16 17
13 Vinylsulfone 70 29 9
doi:10.1371/journal.pntd.0001023.t001
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thought to act irreversibly (vinylsulfones, fluoromethylketones)
showed time-dependent inhibition while those thought to confer
reversible inhibition (e.g., nitriles) showed no time dependence.
Even so, the irreversible inhibitors showed at most a ,10-fold
shift in IC50 value at the longer incubation times. We selected a
5 minute pre-incubation time for profiling the entire library,
reasoning that comparisons of reversible and irreversible inhibitor
potency in vitro is most meaningful with short incubation times,
during the pre-covalent stage of inhibition by irreversible
inhibitors.
Figure 2. Comparing percent inhibition of compounds between cysteine proteases. Single-point inhibition data for rhodesain (Y-axis, %
inhibition at 0.1 mM test compound) as compared to other parasite enzymes (X-axes), including: (A) cruzain (% inhibition at 0.1 mM), (B) falcipain-3 (%
inhibition at 0.05 mM), (C) TbCatB (% inhibition at 1 mM), and (D) trypanathione reductase (% inhibition at 10 mM). Individual data points are colored
according to warhead/P1 type as follows: vinylsulfones (red), nitriles unsubstituted or monosubstituted at P1 (blue), nitriles with geminal cyclic
substitution at P1 (light blue), keto-heterocycles (green), hydroxy/alkoxy ketones (yellow) and others (grey). The shape of each data point
corresponds to the P2 chemotype as follows: phenylalanine (triangle), benzyl cysteine or homphenylalanine (needle); naphthalene (circle), spirocyclic
(open circle), dihalogenated phenylalanine (diamond), leucine/leucine-like (square) and others (open square).
doi:10.1371/journal.pntd.0001023.g002
New Antiparasitic Drug Leads
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Single-point protease inhibition data were determined for the
entire 2157 member library against the proteases cruzain, rhodesain,
TbCatB, and falcipain-3. Falcipain-2 was not screened against but
used only to test falcipain-3 hits. Protease inhibition was determined
using standard functional assays [42,43] employing fluorogenic
substrates (Z-Phe-Arg-AMC or Z-Leu-Arg-AMC) and inhibitor
concentrations of 50 nM (falcipain-3), 100 nM (cruzain and
rhodesain), or 1 mM (TbCatB). To control for possible non-specific
electrophilic inactivation of enzyme by test compounds, we also
screened the library against trypanothione reductase, a non-protease
that nonetheless contains catalytic active-site cysteine functionality.
This latter assay was carried out according to an established method
[44] but at a relatively high inhibitor concentration (10 mM) due to
the expectation that the protease-targeted compound library would
not potently inhibit trypanothione reductase.
Single-point screening data are presented as scatterplots and
color/shape-coded according to warhead/P2 chemotype, as SAR
at these positions provide the most useful information about
substrate/inhibitor specificity (Figure 2). Hence, the cathepsin L-
like proteases rhodesain and cruzain show a similar substrate-
mimetic specificity, with the data points falling roughly along the
diagonal of the scatterplot (Figure 2, panel A). The most potent
inhibitors of these enzymes were vinylsulfones possessing Phe or
similar (e.g. napthylalanine) P2 substituents. Also notable are a
small number of rhodesain-selective analogs, many of which are
characterized by the presence of more extended P2 side chains.
The inhibition profile of falcipain-3 and TbCatB are distinct from
that of either rhodesain or cruzain (panels B and C). Most of the
potent inhibitors of falcipain-3 possess smaller Leu-like P2 moieties
rather than the larger P2 side chains preferred by rhodesain (panel
B). A small number of primarily ketone-based inhibitors were
identified that significantly inhibit both proteases (panel B, green
needles and green squares). Only a handful of library compounds
inhibited TbCatB to a significant extent but strikingly, many of
those that did possess large P2 moieties such as halogenated Phe/
Tyr or napthylalanine (panel C, circles and needles). Furthermore,
whereas the P2 halogenated Phe/Tyr analogs were selective for
TbCatB over rhodesain, the P2 napthylalanine analogs inhibited
both proteases potently. Conversely, P2 phenylalanine analogs
bearing a vinylsulfone warhead proved highly selective for
Figure 3. Fifty percent inhibition concentrations. IC50, (mM) against five parasite cysteine proteases as determined for library compounds that
qualified as hits from the single point screens. Data points above the dashed line had no measurable IC50 (i.e., IC50.25 mM). Data points are colored
and shaped by chemotype, as described in Figure 2.
doi:10.1371/journal.pntd.0001023.g003
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rhodesain over TbCatB (panel C, red triangles). Few inhibitors of
trypanothione reductase were identified (even at 10 mM) and, as
expected, no correlation between protease inhibition and inhibi-
tion of trypanothione reductase could be discerned (panel D).
Thus, the single-concentration screening data provided useful
insight into the substrate/inhibitor preferences of the various
parasite proteases and set the stage for more careful profiling of
specific compounds from the library.
The most potent inhibitors identified in the single-point screen
(3–6% of the total library depending on enzyme) were subse-
quently evaluated in full dose-response to generate IC50 values for
rhodesain, cruzain, TbCatB and falcipain-3. All falcipain-3
inhibitors were also tested against falcipain-2. The results are
presented graphically in Figure 3, where it can be seen that a
significant number of potent falcipain-2/3 and rhodesain/cruzain
inhibitors, but many fewer potent inhibitors of TbCatB, were
identified. Falcipain hits narrowly clustered at sub-micromolar
IC50 with nitrile P1 warhead and leu-like P2 chemotypes
predominating, while rhodesain/cruzain hits were more distrib-
uted in activity and chemical class. Accordingly, while more than
one hundred falcipain-2/3 inhibitors were tested against cultured
W2 P. falciparum parasites, only around thirty inhibitors of the
trypanosome proteases were judged suitable for testing against T.
brucei brucei and/or T. cruzi parasites. The entire library was
examined for cytotoxicity to a mammalian cell line (Jurkat) at a
concentration of 10 mM, and those compounds studied in the T.
cruzi assay were also evaluated for toxicity (at 20 mM) toward the
host BESM cells used in that assay. Parasite growth inhibition
(GI50) and Jurkat/BESM cell cytotoxicity data are presented
graphically in Figure 4. Nearly half of the falcipain inhibitors
examined were found to inhibit parasite growth at low or sub-
micromolar concentrations and without apparent cytotoxicity to
Jurkat cells. A much smaller number of inhibitors were effective
against T. brucei brucei or T. cruzi parasites and many of these were
also cytotoxic to either Jurkat or BESM cells. The most promising
parasite-active lead compounds are discussed in more detail below.
Discussion
The parasite-active and non-cytotoxic analogs identified in the
study can be considered as good candidates for future lead
optimization efforts targeting parasitic indications. As starting
points for such optimization, these compounds are likely more
‘advanced’ than compounds identified from typical screening
Figure 4. Growth inhibition of parasites. GI50 (mM) data for selected library members against cultured P. falciparum (W2 strain), T. brucei brucei, or
T. cruzi parasites. Data points above the dotted line had no measurable GI50 (i.e., GI50.25 mM). Data points are colored and shaped by chemotype as
described in Figure 2. The relative area of data points reflects cytotoxicity to mammalian cell lines (larger squares demoting increasing % growth
inhibition relative to a 100% inhibition control). Cytotoxicity evaluations were performed in Jurkat cells for the T. brucei and P. falciparum actives (at
10 mM test compound) and in BESM cells for the T. cruzi actives (at 20 test mM compound).
doi:10.1371/journal.pntd.0001023.g004
New Antiparasitic Drug Leads
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libraries, as they were synthesized in the course of lead
optimization campaigns targeting cathepsins. More than 85% of
the library compounds have one or zero violations of Lipinski’s
‘rule-of-five’ [46] and can therefore be regarded as having
reasonable prospects for oral bioavailability. The structures and
associated data are provided for ,25 such lead compounds
(Figures 5–6; Tables 2–5). The data presented in the tables
includes historical inhibition values (Ki) against human cathepsin
L and cathepsin B (data provided by Celera Genomics). As noted
above, a significant number of compounds were identified that
possess low- or sub-micromolar activity against cultured P.
falciparum parasites. That so many plasmodium-active compounds
were identified can be attributed to the known substrate preference
of falcipains for leucine-like P2 side chains [47] which are very
highly represented in the library (Figure 1). In fact, a leucine or
leucine-like P2 side chain is found in nearly all of the anti-malarial
lead compounds identified (compounds 14–21, Figures 5 & 6).
Among the antimalarial lead compounds identified, a notable
subset was found to possess a thiophene ring at the N-terminal (P3)
position (Table 2). These analogs (14a–d) are substituted on the
thiophene ring with one (14b–d) or two (14a) aryl or heteroaryl
rings. Enzyme potencies for these analogs were in the mid-low
nanomolar range while GI50 values were low single-digit
micromolar. The structurally related thiophene analogs 15a–b
demonstrated potencies similar to 14a, but while compound 15a
with a trifluoromethyl substituent was similarly effective against
cultured P. falciparum parasites, the analogous phenyl substituted
congener 15b surprisingly was not. Inhibitors 14a–d and 15a–b
were not cytotoxic to Jurkat cells at 10 mM, and inhibited human
cathepsin L and B about 10 and 1000-fold less potently than the
parasite proteases.
Analogs bearing para-biphenyl (16a–d) or meta-biphenyl (17a–
c) P3 substituents represent a second class of anti-plasmodium lead
compounds identified in this study (Table 3). The terminal aryl
ring in these analogs appears to be insensitive to substitution
pattern or type, with electron withdrawing or donating substitu-
ents well tolerated in various positions. Interestingly, the most cell-
active analogs in this subset were 16a and 17a, both of which
possess a methylsulfone substituent on the distal aryl ring. Indeed,
analog 17a is perhaps the most interesting lead compound in this
set, with a sub-micromolar GI50 value, selectivity over the human
cathepsins, and lead-like properties (MW,425, clogP,1.25) that
would leave sufficient room to maneuver in a lead optimization
campaign.
Two of the most potent analogs identified were vinylsulfone-
based inhibitors of the type represented by 18a–b (Table 4). In
fact, compound 18a was previously reported to be an inhibitor of
P. falciparum growth, and structure-activity studies of similar
compounds have been published [48]. A series of ketobenzox-
azole-based analogs (19a–c) were also identified as potent
inhibitors of falcipain-2/3 and P. falciparum growth in culture.
Aside from the P1/warhead moiety, ketobenzoxazole 19a is
otherwise identical to the vinylsulfones 18a–b, and indeed these
compounds exhibit similar IC50 values against falcipain-2/3.
Despite these similarities, the irreversible inhibitors 18a and 18b
inhibited parasite growth at ,100-fold lower concentrations than
did the reversible inhibitor 19a. It is not clear whether this effect is
due to the nature of inhibition or other factors such as cell
Figure 5. Anti-plasmodium lead compounds. Chemical structures of protease inhibitors discussed in the text. Associated enzyme inhibition and
growth inhibition data is provided in tables 2–4.
doi:10.1371/journal.pntd.0001023.g005
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Figure 6. Anti-trypanosomal lead compounds. Chemical structures of protease inhibitors discussed in the text. Associated enzyme inhibition
and growth inhibition data is provided in tables 4–5.
doi:10.1371/journal.pntd.0001023.g006
Table 2. Selected anti-plasmodium lead compounds with associated biochemical and cell-based assay data.
IC50 (mM) Ki (mM) GI50 (mM)
Cytotoxicity (%
inhibition at 10 mM)
cmpd R1 R2 R3 falcipain-2 falcipain-3 catL catB P. falc. W2 Jurkat cells
14a furyl furyl — 0.020 0.029 0.076 16 1.5 ,5%
14b o-ClPh H — 0.0087 0.023 0.71 1.3 2.0 ,5%
14c H p-MeOPh — 0.018 0.025 0.35 4.2 2.7 ,5%
14d Cl furyl — 0.017 0.014 0.28 18 3.9 ,5%
15a — — CF3 0.050 0.015 0.15 54 3.5 ,5%
15b — — Ph 0.024 0.0052 0.11 90 .20 ,5%
doi:10.1371/journal.pntd.0001023.t002
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permeability, warhead inactivation (e.g. ketone reduction), or
inhibition of other as-yet unidentified targets in the parasite.
Nitrile-based inhibitors 20 and 21 are also of significant interest
as lead compounds as they represent the only reversible inhibitors
identified that exhibited sub-micromolar GI50 values against P.
falciparum parasites. Both inhibitors possess an aliphatic nitrile
warhead geminally di-substituted at the P1 position and are thus
structurally distinct from the aromatic nitriles (cyanopyrimidines)
reported recently as potent inhibitors of falcipains [25]. The
introduction of cyclic P1 moieties (as in 20 and 21) has been
reported previously [49] as a strategy to counter peptidase-
mediated drug degradation in vivo and it seems plausible that these
analogs may have been originally synthesized with such an
objective in mind. Both analogs 20 and 21 have leucine or leucine-
like P2 side chains and extended biphenyl moieties at P3,
compound 21 possessing an interesting heterocyclic surrogate for
the P2/P3 amide bond. The combination of reversible inhibition,
low cytotoxicity, and nanomolar potency against falcipains 2/3
and whole parasites, recommend compound 20 in particular for
further lead optimization studies.
Whereas a number of promising antimalarial lead compounds
were identified in this study, very few compounds of clear merit
were uncovered as leads for trypanosomal disease. In fact, the
most potent antitypanosomal compound identified (22) appears
not to be a protease inhibitor at all – having no apparent warhead
function. While compound 22 did not inhibit the growth of Jurkat
cells at 10 mM, it did significantly inhibit the growth of BESM cells
(,90% inhibition at 20 mM). It therefore seems likely that
compound 22 confers its antitrypanosomal effect via a mechanism
other than protease inhibition. While this is not in itself
problematic, a mechanism of drug-like action (as opposed to
non-specific toxicity) would need to be established before further
pursuing compounds like 22.
With respect to likely cysteine protease targets in T. brucei, RNAi
knockdown of TbCatB but not rhodesain was shown to confer a
phenotype similar to treatment with irreversible cysteine protease
inhibitors [17]. Recently published data for small molecule
inhibitors of TbCatB [50] also suggest that TbCatB is the more
important drug target in T. brucei. Of significant interest then are
ketobenzoxazole analogs like 23a and 23b which are potent (low-
mid nM) inhibitors of TbCatB but only weak inhibitors of
rhodesain (Table 5, Figure 6). Both compounds indeed inhibit the
growth of T. brucei brucei parasites, although only at concentrations
at least 100-fold greater than their in vitro IC50 values against
TbCatB (low mM GI50 values vs. mid-low nM IC50 values).
Ketooxadiazole analog 24 possesses excellent in vitro potency
against both TbCatB and rhodesain, and like 23a/b is effective
against cultured T. brucei brucei parasites, but also at relatively high
concentrations (GI50 = 7.0 mM). Ketobenzoxazole analogs 19a
and 19b have quite the opposite selectivity profile of 23a/b and
are ,1000 fold more potent inhibitors of rhodesain than TbCatB.
That these compounds were not effective against T. brucei brucei
parasites even at 25 mM is consistent with the hypothesis that
TbCatB is the more important target in T. brucei. Thus, ketone-
based inhibitors such as 23a–b and 24 represent promising leads
with regard to in vitro potency and selectivity (for 23a–b) but would
Table 3. Selected anti-plasmodium lead compounds with associated enzyme and cell-based data.
IC50 (mM) Ki (mM) GI50 (mM)
Cytotoxicity (%
inhibition at 10 mM)
cmpd R1/R2 falcipain-2 falcipain-3 catL catB P. falc. W2 Jurkat cells
16a 4-(MeSO2)Ph- 0.028 0.018 0.31 2.0 2.2 ,5%
16b 3-(MeO)Ph- 0.075 0.067 0.68 1.6 3.5 ,5%
16c 4-(HO)Ph- 0.078 0.028 4.3 5.2 4.0 ,5%
16d 2-F-Ph- 0.068 0.085 48 20 .20 ,5%
17a 2-(MeSO2)Ph- 0.017 0.016 2.2 18 0.84 ,5%
17b 3-(MeS)Ph- 0.0088 0.028 0.11 5.7 3.0 ,5%
17c 2-(Me)Ph- 0.026 0.067 0.22 24 .20 ,5%
doi:10.1371/journal.pntd.0001023.t003
Table 4. Selected anti-plasmodium lead compounds with associated enzyme and cell-based data.
IC50 (mM) Ki (mM) GI50 (mM)
Cytotoxicity (% inhibition
at 10 mM)
cmpd falcipain-2 falcipain-3 catL catB P. falc. W2 Jurkat cells
18a 0.0076 0.040 0.003 0.44 0.02 ,5%
18b 0.0036 0.029 0.0009 0.21 0.04 ,5%
19a 0.0021 0.0083 0.026 0.125 1.2 ,5%
19b 0.0044 0.0049 0.18 0.042 2.9 ,5%
19c 0.066 0.017 0.61 0.92 4.8 ,5%
20 0.0075 0.011 — — 0.17 ,5%
21 0.0020 0.0024 0.032 6.7 0.87 ,5%
doi:10.1371/journal.pntd.0001023.t004
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require further optimization for enhanced activity in cells. Possibly
poor permeability and/or instability of the ketone warhead
function in these compounds can explain their relatively modest
activity against whole parasites.
A selection of potent cruzain inhibitors with diverse warhead
types were selected for study in T. cruzi infected BESM cells using a
microscopy-based high-content assay (Figure 7). Interestingly, the
ketobenzoxazole analogs described above as active in T. brucei
brucei were also among the most effective compounds against T.
cruzi parasites. This is perhaps not surprising, since nearly all of
these analogs are low nanomolar inhibitors of cruzain in vitro
(Table 5). The most effective inhibitors were 23b and 24, but as
was the case in T brucei, these compounds exert their effects on
parasites only at much higher concentrations than are required to
inhibit the target enzyme in vitro. As noted above, further chemical
optimization of these leads for improved permeability and/or
stability will likely be required to realize their full potential to affect
parasite growth in vitro and in vivo. Also in favor of these
compounds is their reversible-covalent nature of inhibition, which
might be preferable to irreversible inhibitors with respect to the
potential for in vivo toxicity and/or immunogenicity.
Comparisons of in vitro potency in biochemical assays with
parasite growth inhibition is always problematic since factors such
as cell permeability, compound stability, and sub-cellular locali-
zation are not always well understood and can vary with structure
in unpredictable ways. Neither is it possible to rule out a role for as
yet unidentified protease or non-protease targets as contributing to
the observed parasite growth inhibition, since it is very likely that
none of the protease inhibitors discussed herein is perfectly
selective for the intended target(s). We have generally limited
direct comparisons of potency to congeneric chemical series that
inhibit by similar mechanisms (i.e., have similar warheads). For
example, our discussion of protease targets in T. brucei is focused on
reversible ketone-based inhibitors because the in vitro selectivity of
such compounds is more likely to translate to the intracellular
context than would selectivity data for irreversible inhibitors that
exhibit time-dependent protease inhibition. We have similarly
chosen not to make overreaching conclusions about the relative
potency of compounds against parasite and human proteases, as
the latter data were generated at an earlier time in a different
laboratory (and furthermore were determined as Ki values rather
than the IC50 values provided for the parasite proteases). We
nonetheless felt it was valuable to include this historical cathepsin
data as it provides some qualitative indication of the potential
selectivity of the analogs described.
The market forces that spur new pharmaceutical development
in the developed world are typically absent in the case of tropical
parasitic diseases, despite indisputable medical need. One strategy
to address this discrepancy is to focus on anti-parasitic drug targets
that are homologous to other targets that are being actively
Table 5. Selected anti-trypanosomal lead compounds with associated enzyme and cell-based data.
IC50 (mM) Ki (mM) GI50 (mM)
Cytotoxicity (%
inhibition at 10 mM)
cmpd rhodesain TbCatB cruzain catL catB T. brucei T. cruzi Jurkat cells
19a 0.001 1.0 0.001 0.026 0.125 .25 20.0 ,5%
19b 0.001 0.6 0.004 0.18 0.042 .25 10.9 ,5%
22 0.64 .100 1.6 0.071 4.5 0.20 0.80 ,5%
23a 3.9 0.07 0.03 1.1 0.32 4.2 19 ,5%
23b 5.0 0.001 0.38 0.28 0.61 10.5 7.7 ,5%
24 0.006 0.05 0.01 0.018 0.0016 7.0 7.6 ,5%
doi:10.1371/journal.pntd.0001023.t005
Figure 7. T. cruzi growth inhibition of compounds 24. Representative fluorescent images acquired with the IN Cell Analyzer 2000, taken with
206objective magnification at Ex 350 nm/Em 460 nm, showing the host BESM nuclei (red outline) and surrounding smaller T. cruzi kinetoplastids
(blue outline). (A) 1% DMSO as 0% inhibition control; (B) compound 24 at the highest assay concentration of 20 mM; (C) GI50 dose response plots of
compound 24 against T. cruzi and cytotoxicity to host BESM cells.
doi:10.1371/journal.pntd.0001023.g007
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pursued in the industry. As demonstrated here, this approach can
produce potent and cell-active lead compounds directly out of a
primary screening campaign. Many of these compounds are
already good candidates for initial evaluation in animal pharma-
cokinetic and pharmacodynamic studies. Progress towards the
identification of viable clinical candidates would require a robust
lead optimization campaign to improve in vivo efficacy and
address any safety issues that emerge. This work is far from trivial
and will require significant resources in synthetic chemistry and
animal pharmacology and toxicology. Providing encouragement
for such work, however, is the knowledge that nitrile- and ketone-
based cathepsin inhibitors not unlike those described herein have
been successfully progressed into human clinical trials for other
therapeutic indications.
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